Early and accurate diagnosis is therefore of outmost importance and the presence of autoantibodies to citrullinated proteins/peptide (anti-CCP) has an important prognostic value for the disease.
These antibodies can be detected even before the onset of clinical symptoms. The anti-CCP2 test has a very high specificity and sensitivity and is a reliable and accurate toolset for the early diagnosis and follow-up of RA. Due to its wide clinical use, anti-CCP is included in the ACR/EULAR criteria for diagnosing RA.
Since the first report in 1998 that antibodies reacting with synthetic pep-tides containing the amino acid citrulline are highly specific for RA, the measurement of anti-CCP antibodies has become the method of choice in the accurate diagnosis of this disease.
The Svar CCP portfolio consists of enzyme-linked immunosorbent assay (ELISA) for detection and semi-quantitation of IgG antibodies to Cyclic Citrullinated Peptides (CCP) as well as rapid test for fast, near-patient diagnosis.